Merck & Company Inc (MRK) - Net Assets
Based on the latest financial reports, Merck & Company Inc (MRK) has net assets worth $45.93 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($128.69 Billion) and total liabilities ($82.75 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Merck & Company Inc (MRK) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $45.93 Billion |
| % of Total Assets | 35.69% |
| Annual Growth Rate | 7.78% |
| 5-Year Change | 37.65% |
| 10-Year Change | 30.65% |
| Growth Volatility | 35.78 |
Merck & Company Inc - Net Assets Trend (1985–2025)
This chart illustrates how Merck & Company Inc's net assets have evolved over time, based on quarterly financial data. See MRK cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Merck & Company Inc (1985–2025)
The table below shows the annual net assets of Merck & Company Inc from 1985 to 2025. For live valuation and market cap data, see how much is Merck & Company Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $52.66 Billion | +13.56% |
| 2024-12-31 | $46.37 Billion | +23.22% |
| 2023-12-31 | $37.63 Billion | -18.29% |
| 2022-12-31 | $46.06 Billion | +20.39% |
| 2021-12-31 | $38.26 Billion | +50.59% |
| 2020-12-31 | $25.40 Billion | -2.30% |
| 2019-12-31 | $26.00 Billion | -3.28% |
| 2018-12-31 | $26.88 Billion | -22.24% |
| 2017-12-31 | $34.57 Billion | -14.24% |
| 2016-12-31 | $40.31 Billion | -9.96% |
| 2015-12-31 | $44.77 Billion | -8.25% |
| 2014-12-31 | $48.79 Billion | -6.76% |
| 2013-12-31 | $52.33 Billion | -5.66% |
| 2012-12-31 | $55.46 Billion | -2.60% |
| 2011-12-31 | $56.94 Billion | +0.24% |
| 2010-12-31 | $56.80 Billion | -7.61% |
| 2009-12-31 | $61.48 Billion | +190.47% |
| 2008-12-31 | $21.17 Billion | +2.80% |
| 2007-12-31 | $20.59 Billion | +3.13% |
| 2006-12-31 | $19.97 Billion | -2.06% |
| 2005-12-31 | $20.38 Billion | +3.50% |
| 2004-12-31 | $19.70 Billion | +1.04% |
| 2003-12-31 | $19.49 Billion | -15.73% |
| 2002-12-31 | $23.13 Billion | +10.73% |
| 2001-12-31 | $20.89 Billion | +5.21% |
| 2000-12-31 | $19.85 Billion | +18.87% |
| 1999-12-31 | $16.70 Billion | +1.18% |
| 1998-12-31 | $16.51 Billion | +19.96% |
| 1997-12-31 | $13.76 Billion | -3.64% |
| 1996-12-31 | $14.28 Billion | +1.84% |
| 1995-12-31 | $14.02 Billion | +13.56% |
| 1994-12-31 | $12.35 Billion | +10.58% |
| 1993-12-31 | $11.17 Billion | +98.33% |
| 1992-12-31 | $5.63 Billion | +2.16% |
| 1991-12-31 | $5.51 Billion | +25.71% |
| 1990-12-31 | $4.38 Billion | +8.76% |
| 1989-12-31 | $4.03 Billion | +41.13% |
| 1988-12-31 | $2.86 Billion | +34.92% |
| 1987-12-31 | $2.12 Billion | -17.61% |
| 1986-12-31 | $2.57 Billion | -2.46% |
| 1985-12-31 | $2.63 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Merck & Company Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2351.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $73.08 Billion | 138.91% |
| Common Stock | $1.79 Billion | 3.40% |
| Other Comprehensive Income | $-4.29 Billion | -8.15% |
| Total Equity | $52.61 Billion | 100.00% |
Merck & Company Inc Competitors by Market Cap
The table below lists competitors of Merck & Company Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Novartis AG ADR
NYSE:NVS
|
$281.41 Billion |
|
Novartis AG
MX:NVSN
|
$281.45 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
$282.04 Billion |
|
Industrial and Commercial Bank of China Ltd
SHG:601398
|
$282.48 Billion |
|
GE Vernova LLC
NYSE:GEV
|
$279.51 Billion |
|
Philip Morris International Inc
NYSE:PM
|
$278.05 Billion |
|
AstraZeneca PLC
NYSE:AZN
|
$271.29 Billion |
|
Roche Holding AG
SW:ROG
|
$256.43 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Merck & Company Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 46,313,000,000 to 52,606,000,000, a change of 6,293,000,000 (13.6%).
- Net income of 18,254,000,000 contributed positively to equity growth.
- Dividend payments of 8,176,000,000 reduced retained earnings.
- Share repurchases of 5,084,000,000 reduced equity.
- Other comprehensive income increased equity by 658,000,000.
- Other factors increased equity by 641,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $18.25 Billion | +34.7% |
| Dividends Paid | $8.18 Billion | -15.54% |
| Share Repurchases | $5.08 Billion | -9.66% |
| Other Comprehensive Income | $658.00 Million | +1.25% |
| Other Changes | $641.00 Million | +1.22% |
| Total Change | $- | 13.59% |
Book Value vs Market Value Analysis
This analysis compares Merck & Company Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.43x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 111.14x to 5.43x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $1.02 | $113.87 | x |
| 1986-12-31 | $1.03 | $113.87 | x |
| 1987-12-31 | $0.86 | $113.87 | x |
| 1988-12-31 | $1.21 | $113.87 | x |
| 1989-12-31 | $1.48 | $113.87 | x |
| 1990-12-31 | $1.64 | $113.87 | x |
| 1991-12-31 | $2.11 | $113.87 | x |
| 1992-12-31 | $2.65 | $113.87 | x |
| 1993-12-31 | $4.30 | $113.87 | x |
| 1994-12-31 | $4.36 | $113.87 | x |
| 1995-12-31 | $4.62 | $113.87 | x |
| 1996-12-31 | $4.81 | $113.87 | x |
| 1997-12-31 | $5.10 | $113.87 | x |
| 1998-12-31 | $5.24 | $113.87 | x |
| 1999-12-31 | $5.51 | $113.87 | x |
| 2000-12-31 | $6.30 | $113.87 | x |
| 2001-12-31 | $6.91 | $113.87 | x |
| 2002-12-31 | $7.99 | $113.87 | x |
| 2003-12-31 | $6.91 | $113.87 | x |
| 2004-12-31 | $7.77 | $113.87 | x |
| 2005-12-31 | $8.17 | $113.87 | x |
| 2006-12-31 | $8.03 | $113.87 | x |
| 2007-12-31 | $8.29 | $113.87 | x |
| 2008-12-31 | $8.75 | $113.87 | x |
| 2009-12-31 | $25.98 | $113.87 | x |
| 2010-12-31 | $17.43 | $113.87 | x |
| 2011-12-31 | $17.62 | $113.87 | x |
| 2012-12-31 | $17.24 | $113.87 | x |
| 2013-12-31 | $16.61 | $113.87 | x |
| 2014-12-31 | $16.61 | $113.87 | x |
| 2015-12-31 | $15.73 | $113.87 | x |
| 2016-12-31 | $14.38 | $113.87 | x |
| 2017-12-31 | $12.49 | $113.87 | x |
| 2018-12-31 | $9.97 | $113.87 | x |
| 2019-12-31 | $10.04 | $113.87 | x |
| 2020-12-31 | $9.96 | $113.87 | x |
| 2021-12-31 | $15.04 | $113.87 | x |
| 2022-12-31 | $18.09 | $113.87 | x |
| 2023-12-31 | $14.76 | $113.87 | x |
| 2024-12-31 | $18.23 | $113.87 | x |
| 2025-12-31 | $20.98 | $113.87 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Merck & Company Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 34.70%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 28.12%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 2.60x
- Recent ROE (34.70%) is above the historical average (28.98%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | 20.50% | 15.22% | 0.72x | 1.86x | $276.50 Million |
| 1986 | 26.30% | 16.37% | 0.81x | 1.99x | $418.79 Million |
| 1987 | 42.82% | 17.91% | 0.89x | 2.68x | $694.73 Million |
| 1988 | 42.26% | 20.32% | 0.97x | 2.15x | $921.22 Million |
| 1989 | 42.48% | 22.83% | 0.97x | 1.92x | $1.14 Billion |
| 1990 | 46.45% | 23.22% | 0.96x | 2.09x | $1.40 Billion |
| 1991 | 43.16% | 24.66% | 0.91x | 1.93x | $1.63 Billion |
| 1992 | 39.66% | 20.54% | 0.87x | 2.22x | $1.48 Billion |
| 1993 | 21.62% | 20.63% | 0.53x | 1.99x | $1.16 Billion |
| 1994 | 26.91% | 20.02% | 0.68x | 1.96x | $1.88 Billion |
| 1995 | 28.42% | 19.99% | 0.70x | 2.03x | $2.16 Billion |
| 1996 | 32.42% | 19.57% | 0.82x | 2.03x | $2.68 Billion |
| 1997 | 36.64% | 19.52% | 0.92x | 2.04x | $3.35 Billion |
| 1998 | 41.00% | 19.51% | 0.84x | 2.49x | $3.97 Billion |
| 1999 | 44.48% | 18.01% | 0.92x | 2.69x | $4.57 Billion |
| 2000 | 45.99% | 16.90% | 1.01x | 2.69x | $5.34 Billion |
| 2001 | 45.37% | 34.35% | 0.48x | 2.74x | $5.68 Billion |
| 2002 | 39.28% | 33.34% | 0.45x | 2.61x | $5.33 Billion |
| 2003 | 43.85% | 30.38% | 0.55x | 2.61x | $5.27 Billion |
| 2004 | 33.72% | 25.38% | 0.54x | 2.46x | $4.10 Billion |
| 2005 | 25.76% | 21.04% | 0.49x | 2.49x | $2.83 Billion |
| 2006 | 25.25% | 19.59% | 0.51x | 2.54x | $2.68 Billion |
| 2007 | 18.01% | 13.54% | 0.50x | 2.66x | $1.46 Billion |
| 2008 | 41.62% | 32.74% | 0.51x | 2.52x | $5.93 Billion |
| 2009 | 21.84% | 47.03% | 0.24x | 1.90x | $6.99 Billion |
| 2010 | 1.58% | 1.87% | 0.43x | 1.95x | $-4.58 Billion |
| 2011 | 11.50% | 13.05% | 0.46x | 1.93x | $820.30 Million |
| 2012 | 11.63% | 13.05% | 0.45x | 2.00x | $866.00 Million |
| 2013 | 8.85% | 10.00% | 0.42x | 2.12x | $-572.50 Million |
| 2014 | 24.50% | 28.22% | 0.43x | 2.02x | $7.06 Billion |
| 2015 | 9.94% | 11.25% | 0.39x | 2.28x | $-25.60 Million |
| 2016 | 9.78% | 9.85% | 0.42x | 2.38x | $-88.80 Million |
| 2017 | 6.97% | 5.97% | 0.46x | 2.56x | $-1.04 Billion |
| 2018 | 23.30% | 14.71% | 0.51x | 3.09x | $3.55 Billion |
| 2019 | 37.99% | 25.16% | 0.46x | 3.26x | $7.25 Billion |
| 2020 | 27.91% | 17.02% | 0.45x | 3.62x | $4.54 Billion |
| 2021 | 34.17% | 26.79% | 0.46x | 2.77x | $9.23 Billion |
| 2022 | 31.57% | 24.49% | 0.54x | 2.37x | $9.92 Billion |
| 2023 | 0.97% | 0.61% | 0.56x | 2.84x | $-3.39 Billion |
| 2024 | 36.96% | 26.68% | 0.55x | 2.53x | $12.49 Billion |
| 2025 | 34.70% | 28.12% | 0.47x | 2.60x | $12.99 Billion |
Industry Comparison
This section compares Merck & Company Inc's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $11,357,258,390
- Average return on equity (ROE) among peers: 24.09%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Merck & Company Inc (MRK) | $45.93 Billion | 20.50% | 1.80x | $281.24 Billion |
| AbbVie Inc (ABBV) | $1.74 Billion | 101.84% | 14.79x | $356.49 Billion |
| Amgen Inc (AMGN) | $20.39 Billion | 20.58% | 0.79x | $181.97 Billion |
| Amarin Corporation PLC (AMRN) | $37.84 Million | -71.15% | 0.29x | $315.59 Million |
| AstraZeneca PLC (AZN) | $2.73 Billion | 25.42% | 1.69x | $282.04 Billion |
| AstraZeneca PLC (AZN) | $23.25 Billion | 10.99% | 1.40x | $271.29 Billion |
| Biogen Inc (BIIB) | $67.90 Million | -33.28% | 0.19x | $27.74 Billion |
| Bristol-Myers Squibb Company (BMY) | $6.02 Billion | 32.59% | 0.79x | $110.27 Billion |
| Gilead Sciences Inc (GILD) | $19.11 Billion | 94.74% | 1.71x | $153.55 Billion |
| GlaxoSmithKline PLC ADR (GSK) | $15.99 Billion | 35.74% | 2.81x | $111.15 Billion |
| Johnson & Johnson (JNJ) | $24.23 Billion | 23.39% | 0.59x | $550.26 Billion |
About Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, a… Read more